INSIGHTS ON DRUG DEVELOPMENT

• Overcoming Excipient Risks And Challenges For Parenteral Formulations

  Excipients are essential to parenteral formulations, which help protect APIs, enhance stability, and ensure safety. Learn how strategic excipient selection can optimize drug performance and patient outcomes.

• Method Development For Forced Degradation Of GLP-1 Agonist

  Gain insight into how a systematic approach reveals impurity behavior, strengthens selectivity, and refines chromatographic conditions to build a reliable degradation method for a GLP‑1 agonist.

• Leveraging Inductively Coupled Plasma Mass Spectrometry

  Explore how utilizing ICP-MS can help pharmaceutical companies ensure the safety and effectiveness of their products, ultimately benefiting both patients and the industry as a whole.

• T3P – A Green Solution For Peptide Coupling, Water Removal Reactions

  The session focuses on the use of T3P (propanephosphonic acid anhydride) in amidation and peptide coupling reactions, including both liquid-phase and solid-phase peptide synthesis.

• Nitrosamine Testing: How To Ensure Regulatory Compliance, Product Safety

  9/16/2025

  Explore what nitrosamines are, why testing matters, and how we're able to deliver high-confidence solutions through advanced science and industry-leading expertise.

• API In Capsule Vs. The Lost Art Of Formulation Development

  11/5/2025

  API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.

• Rapid Walkaway Solution For Assessing Viability In Cancer Organoids

  3/31/2025

  Assess anti-cancer compounds' effects on organoid size and morphology with colorectal cancer organoids as well as discover automated imaging and viability assays to streamline drug screening and aid early identification.

• Navigating Preclinical Drug Development Challenges With Lipid-Based Formulations

  3/20/2026

  Maximize the oral bioavailability of challenging small-molecule candidates and streamline the path from preclinical toxicology to clinical trials by leveraging optimized lipid-based formulations.

• Democratizing Organ-On-A-Chip Technology

  4/22/2024

  Learn about drug development challenges, the evolution of in vitro cell culture towards greater human relevance, a complete solution for creating human-relevant and translatable models, and more.